Fenofibrate Dosing in Impaired Renal Function

Dosing Recommendations

The American College of Cardiology recommends that fenofibrate should not be used in patients with severe renal impairment (eGFR <30 mL/min/1.73m²), and the dose should not exceed 54 mg/day in patients with moderate renal impairment (eGFR 30-59 mL/min/1.73m²) 1
For patients with normal renal function or mild renal impairment (eGFR ≥60 mL/min/1.73m²), the standard dose of fenofibrate is 96 mg daily 2, 3
For patients with moderate renal impairment (eGFR 30-59 mL/min/1.73m²), the reduced dose of fenofibrate is 48 mg daily (or maximum 54 mg daily depending on formulation) 1, 2, 3
The American Journal of Kidney Diseases recommends avoiding fenofibrate use in patients with severe renal impairment (eGFR <30 mL/min/1.73m²) and in kidney transplant recipients 1, 2, 3

The American College of Cardiology recommends evaluating renal status before initiating fenofibrate therapy, assessing renal function within 3 months after initiation, and continuing monitoring every 6 months thereafter 1, 4
If eGFR decreases persistently to <30 mL/min/1.73m², fenofibrate should be discontinued 1, 4
The American College of Cardiology also recommends considering the benefits of ASCVD risk reduction or triglyceride lowering against potential adverse effects when using fenofibrate in patients with renal impairment 1, 4
Fenofibrate should not be initiated in patients on statin therapy due to increased risk of muscle symptoms and rhabdomyolysis; if combination therapy is necessary, use with low or moderate-intensity statins only 1, 4

Gemfibrozil may be an alternative fibrate option in patients with severe renal impairment, with a reduced dose of 600 mg daily (compared to standard 1200 mg daily) 2, 3, 5

An acute rise in serum creatinine of approximately 0.13 mg/dL (12 µmol/L) with fenofibrate is expected and does not represent true nephrotoxicity—continue the medication and monitor closely, as this effect is reversible and fenofibrate may actually slow long-term GFR decline, according to the American Journal of Kidney Diseases 6

Discontinue fenofibrate if the patient develops acute kidney injury from intercurrent illness, volume depletion, or concurrent nephrotoxic medications, as recommended by the American Journal of Kidney Diseases 7